Bioventix (BVXP) ShareSoc presentation October 2018

Bioventix ShareSoc presentation: October 2018
By Peter Harrison, CEO.

Includes full year results year ended 30th June 2018.

Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company’s non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.

 

Overview – 00:29
Location and skills – 00:54
Automated blood testing – 01:26
Creating antibodies – 05:35
Why SMA’s? (Testosterone) – 07:49
Why SMA’s? (Troponin) – 10:04
Financial highlights 17/18 – 12:00
BVXP sales 17/18 product mix – 12:58
Key financials – 14:50
New Troponin assays – 15:46
Pipeline Development 2018 – 16:18
Business dynamics – 18:40
Selected shareholder base – 22:05
Bioventix Directors – 22:42
Conclusion and outlook – 23:19
Q&A – 24:39

 

The presentation slides can be viewed here.

 

Videos from Bioventix

Bioventix (BVXP) – ShareSoc presentation October 2018
33:33

Bioventix (BVXP) ShareSoc presentation October 2018

Bioventix ShareSoc presentation: October 2018 By Peter Harrison, CEO. Includes full year results year ended 30th June 2018. Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing […]
Bioventix (BVXP) Full Year results June 2016 interview
4
21:17

Bioventix (BVXP) Full Year results June 2016 interview

Length: c 20 mins Peter Harrison, CEO, talks through the latest FY results 30 June 2016 with @tamzinpiworld. He expands on the success of Vitamin D and its future prospects, together with the positive impact of foreign exchange. He goes on to talk about the NT proBNP licence, which comes to an end July 2017, […]
Bioventix – BVXP –  Company overview
07:01

Bioventix – BVXP – Company overview

Introduction to Bioventix (BVXP) by Peter Harrison, CEO Length: c. 6 mins Peter Harrison, CEO, tells us what Bioventix does, and discusses the business model. Essentially BVXP develops antibodies for use in different blood testing machines manufactured by the big names: Roche, Siemens, Abbot, etc. He goes into detail about BVXP antibodies types, and why […]
Bioventix BVXP ShareSoc Richmond 6 6 16
4

Bioventix BVXP ShareSoc Richmond 6 6 16

Peter Harrison CEO Bioventix (BVXP) ShareSoc Richmond 6.6.16 A succinct presentation to understand what BVXP do. • The product • Revenue streams • Stickiness of revenue • Timelines to develop revenue streams • Barriers to entry • Threats • The future A sense of the culture of the company The journey of the historic research […]

You might be interested in

LEAVE YOUR COMMENT

Your email address will not be published. Required fields are marked *